Syon Capital’s Travere Therapeutics TVTX Stock Holding History

Syon Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,435	Closed	-$269K	–	658
2024 Q4	$269K	Buy	+15,435	New	+$273K	0.02%	435

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Syon Capital's TVTX Position: Q1 2025 in Review

Syon Capital sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 15,435 shares — an estimated $269K sold.

Syon Capital first reported a position in TVTX in Q4 2024 and held it in 1 quarter. The position peaked at $269K in Q4 2024. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

Syon Capital reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 15,435 Travere Therapeutics shares in Q1 2025, an estimated $269K.
Syon Capital first reported a position in Travere Therapeutics in Q4 2024 and held it in 1 quarter.
Syon Capital's Travere Therapeutics position peaked at $269K in Q4 2024.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.